Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

1. Any participant unable or not willing to sign inform consent or, in the case of adolescents, not willing to provide assent.

2. Any participant who is currently receiving systemic antibiotics. Topical antibiotics are permitted. Use of metronidazole or rifaximin for treating small intestinal bacterial overgrowth (SIBO) is also permitted.

3. Any participant with visible evidence of compromised skin integrity present at the catheter exist site or catheter exit site infection.

4. Any participant with a secondary CVC in addition to the primary TPN line.

5. Any participant that has received thrombolytic treatment (e.g., tissue-type plasminogen activator \[tPA\]-Cathflo), not as a part of the institution's standard of care for patency management, in current catheter within 30 days of randomization.

6. Any participant with unstable arrhythmia, defined as presence of hemodynamic instability within a month prior to the baseline assessment.

7. Any participant using any type of antimicrobial-coated or heparin-coated catheter.

8. Any participant with documented chronic bleeding diathesis, active or recurrent bleeding within 1 month prior to randomization.

9. Any participant with a congenitally lethal condition or a life expectancy of less than 6 months.

10. Any participant with documented history of an atrial thrombus or known hypercoagulable state.

11. Any participant with an open, non-healing skin ulcer.

12. Any participant who has received an allogeneic hematopoietic stem cell transplant within the last year.

13. Any participant with neutropenia with an absolute neutrophil count \<500 cells/μL

14. Any participant with current requirement for systemic chemotherapy and or immunosuppression and absolute neutrophil count \<500 cells/μL that occured in the past 4 weeks.

15. Any participant with known allergies or absolute contraindications to citrate, taurolidine, pork products, or heparin or a history of heparin-induced thrombocytopenia.

16. Any participant taking other medication with known systemic drug interaction with citrate, taurolidine or heparin.

17. Any participant anticipating receiving an intestinal transplant within 90 days. Participants can be on a transplant list but a participant with a known or anticipated transplant date within 90 days of study entry should be excluded from study participation. A participant who may receive an intestinal transplant \>90 days of study entry may remain on the study as long as they continue to receive TPN.

18. Any participant who is pregnant or lactating.

19. Any participant receiving continuous TPN (infusion over 24 hours).

20. Any participant with any medical conditions that render them unable to, or unlikely to complete the study or would interfere with optimal participation in the study or produce significant risk to participant.

21. Any participants who are participating in another interventional clinical study or planning/anticipating participating in another interventional clinical study, except for non-pharmacological research studies.

What this study is about